High-risk @entity1082 in non-melanoma XXXX from renal allograft recipients and immunocompetent @entity1 .

@entity1 @entity986 @entity75 @entity1489 @entity996 @entity876 @entity1544 @entity1082 @entity5702 @entity272
BACKGROUND: High-risk @entity1 papillomaviruses (HR-HPVs) can be detected in a proportion of @entity1489 . Data on prevalence are inconclusive, but are essential to estimate the relevance of HR-HPV, particularly with regard to prophylactic HPV vaccines for @entity1489 prevention. METHODS: High-risk @entity1082 DNA was investigated in 140 non-melanoma @entity272 from 54 immunocompetent @entity1 and 33 immunosuppressed renal allograft recipients. Expression of @entity986 ( @entity986 ), a marker for HR-HPV oncogene expression in the uterine cervix, and of @entity876 and @entity996 was evaluated immunohistochemically. RESULTS: The highest prevalence of HR-HPV was found in @entity1544 ( @entity1544 ) (46.2% (6 out of 13) in immunosuppressed and 23.5% (4 out of 17) in immunocompetent @entity1 ). High-risk @entity1082 positivity was accompanied by diffuse @entity986 ( @entity986 ) expression in most @entity1544 (P<0.001) and @entity5702 (P=0.02), while almost all @entity1544 in situ were @entity986 ( @entity986 ) positive irrespective of HR-HPV presence (P=0.66). Diffuse @entity986 ( @entity986 ) expression was associated with lack of @entity996 expression (P=0.001). @entity876 was strongly expressed in 40.0% (56 out of 140) of the lesions irrespective of HR-HPV presence. CONCLUSION: High-risk @entity1082 can be detected in lesions of keratinised squamous epithelia. The association of HR-HPV with diffuse @entity986 ( @entity986 ) expression might indicate HR-HPV oncogene expression in a proportion of lesions. Overexpression of @entity876 suggests @entity876 pathway alterations in @entity75 .
